Literature DB >> 26427663

The diagnostic utility of the triple markers Napsin A, TTF-1, and PAX8 in differentiating between primary and metastatic lung carcinomas.

Nehad M R Abd El-Maqsoud1, Ehab Rifat Tawfiek2, Ayman Abdelmeged3, Mohamed Fathy Abdel Rahman4, Alaa A E Moustafa4.   

Abstract

Napsin A and thyroid transcription factor-1 (TTF-1) are useful biomarkers for differentiating lung adenocarcinoma from squamous cell carcinoma and also for differentiating primary lung adenocarcinoma from metastatic lung carcinoma. Pair-boxed 8 (PAX8) can help in distinguishing primary lung carcinoma from metastatic carcinomas and help to determine the primary sites of metastatic carcinomas. Immunohistochemistry for Napsin A, TTF-1, and PAX8 were performed on 193 cases of carcinoma: 50 primary lung carcinoma and 143 carcinomas from other sites. Napsin A and TTF-1 were positive in 54, 52 % of lung carcinomas cases, respectively. While in adenocarcinoma cases, their expressions were 86.7 and 83.3 %, respectively. PAX8 was negative in all lung carcinomas. TTF-1 and PAX8 were positive in 93.3 and 96.7 % of thyroid carcinoma cases and in 87.5 and 93.8 % of papillary carcinoma respectively, and both were positive in 100 % of follicular carcinoma. Napsin A was negative in all thyroid carcinomas. Napsin A and PAX8 were positive in 50 and 93.3 % of renal carcinoma cases and in 81.8 and 100 % of papillary carcinoma, 38.5 and 92.3 % of clear cell carcinoma, and 16.7 and 83.3 % of chromophobe carcinoma respectively. TTF-1 was negative in all renal carcinomas. PAX8 was positive in 80 % of ovarian carcinoma cases; 100 and 60 % of serous mucinous carcinomas, respectively. It was also positive in 100 % of endometrial carcinoma. Napsin A and TTF-1 were negative in both ovarian and endometrial carcinomas. Our data demonstrated that combined use of Napsin A, TTF-1, and PAX8 may help in differentiating between primary lung adenocarcinoma and metastatic lung carcinomas.

Entities:  

Keywords:  Metastatic lung carcinoma; Napsin A; PAX8; Primary lung carcinoma; TTF-1

Mesh:

Substances:

Year:  2015        PMID: 26427663     DOI: 10.1007/s13277-015-3964-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.

Authors:  David Tacha; Ding Zhou; Liang Cheng
Journal:  Appl Immunohistochem Mol Morphol       Date:  2011-07

2.  Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.

Authors:  Stewart M Knoepp; Lakshmi P Kunju; Michael H Roh
Journal:  Diagn Cytopathol       Date:  2010-12-31       Impact factor: 1.582

3.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

4.  A comprehensive analysis of PAX8 expression in human epithelial tumors.

Authors:  Anna R Laury; Ruth Perets; Huiying Piao; Jeffrey F Krane; Justine A Barletta; Christopher French; Lucian R Chirieac; Rosina Lis; Massimo Loda; Jason L Hornick; Ronny Drapkin; Michelle S Hirsch
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

5.  Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma.

Authors:  Tamara L Lotan; Huihui Ye; Jonathan Melamed; Xue-Ru Wu; Ie-Ming Shih; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

6.  Comparative genomics reveals a functional thyroid-specific element in the far upstream region of the PAX8 gene.

Authors:  Roberto Nitsch; Valeria Di Dato; Alessandra di Gennaro; Tiziana de Cristofaro; Serena Abbondante; Mario De Felice; Mariastella Zannini; Roberto Di Lauro
Journal:  BMC Genomics       Date:  2010-05-14       Impact factor: 3.969

7.  PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.

Authors:  Min Wang; Haifen Ma; Yunbao Pan; Weihua Xiao; Junqiang Li; Jihong Yu; Ji He
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-04

8.  Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.

Authors:  Mi Jin Kim; Hyeong Chan Shin; Kyeong Cheol Shin; Jae Y Ro
Journal:  Ann Diagn Pathol       Date:  2012-10-04       Impact factor: 2.090

9.  Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.

Authors:  Daisuke Nonaka; Yunjia Tang; Luis Chiriboga; Michael Rivera; Ronald Ghossein
Journal:  Mod Pathol       Date:  2007-12-14       Impact factor: 7.842

10.  Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors.

Authors:  Mitra Heidarpour; Zahra Tavanafar
Journal:  Adv Biomed Res       Date:  2014-03-25
View more
  9 in total

1.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

Review 2.  Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site.

Authors:  Janick Selves; Elodie Long-Mira; Marie-Christine Mathieu; Philippe Rochaix; Marius Ilié
Journal:  Cancers (Basel)       Date:  2018-04-05       Impact factor: 6.639

3.  Medullary Thyroid Carcinoma Presenting as Metastatic Disease to the Breast.

Authors:  Archana P Kanteti; Samir Atiya; Ashley Hein; Jesse L Cox; Ernesto Martinez Duarte
Journal:  Case Rep Pathol       Date:  2020-05-22

4.  Diagnosis prediction of tumours of unknown origin using ImmunoGenius, a machine learning-based expert system for immunohistochemistry profile interpretation.

Authors:  Yosep Chong; Nishant Thakur; Ji Young Lee; Gyoyeon Hwang; Myungjin Choi; Yejin Kim; Hwanjo Yu; Mee Yon Cho
Journal:  Diagn Pathol       Date:  2021-03-11       Impact factor: 2.644

5.  Joint Detection of Tap and CEA Based on Deep Learning Medical Image Segmentation: Risk Prediction of Thyroid Cancer.

Authors:  Shaolei Lang; Yinxia Xu; Liang Li; Bin Wang; Yang Yang; Yan Xue; Kexin Shi
Journal:  J Healthc Eng       Date:  2021-05-31       Impact factor: 2.682

6.  Bilateral breast adenocarcinomas with EML4-ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?

Authors:  Chao Liu; Lijuan Ding; Bing Sun; Shikai Wu
Journal:  Onco Targets Ther       Date:  2016-06-16       Impact factor: 4.147

7.  Occult ovarian clear-cell carcinoma diagnosed as primary adenocarcinoma of the lung: A case report of a diagnostic pitfall for clinicians and pathologists.

Authors:  Terufumi Kubo; Yoshihiko Hirohashi; Hiromi Fujita; Shintaro Sugita; Yasuhiro Kikuchi; Tomoyo Shinkawa; Munehide Nakatsugawa; Mitsuhiro Tsujiwaki; Yuta Sudo; Yuichiro Asai; Yasuaki Umeda; Hiroki Takahashi; Tadashi Hasegawa; Toshihiko Torigoe
Journal:  Respir Med Case Rep       Date:  2018-10-18

Review 8.  Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management.

Authors:  Marie Nguyen; George He; Alfred King-Yin Lam
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

9.  Napsin A Expression in Human Tumors and Normal Tissues.

Authors:  Sören Weidemann; Jan Lukas Böhle; Hendrina Contreras; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Katharina Möller; Christoph Fraune; Christian Bernreuther; Michael Rink; Ronald Simon; Anne Menz; Andrea Hinsch; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  Pathol Oncol Res       Date:  2021-04-20       Impact factor: 3.201

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.